Have you registered for #ASGCT2025? Secure your spot to join us in New Orleans or virtually at the for the premier event in gene and cell therapy.
In Q1 2025, one new therapy was approved for each of the gene, cell, and RNA categories.
The first quarterly report of 2025 from ASGCT and Citeline is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
Highlights from this issue include:
In the U.S., approvals of Encelto for macular telangiectasia type 2 and Qfitlia for hemophilia A or B
In China, approval of Ruiboshen, the country's first mesenchymal stem cell therapy, for steroid-refractory acute graft-versus-host disease
Continued increase—up to 74% from 58%—in non-genetically modified cell therapy trials initiated for non-oncology indications
Read + download the report
May 13-17, 2025 | New Orleans
© 2000-2025 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico